Target intelligence / Profile preview

DNA damage-binding protein 1 (DDB1)

Target
DDB1
Molecular classification
Adaptor/scaffold protein, DNA-binding protein, Component of cullin-RING E3 ubiquitin ligase complexes (specifically CUL4-DDB1), WD40 repeat protein
01

Overview

DNA damage-binding protein 1 (DDB1) is a highly conserved, large (127 kDa) protein that forms a core component of the CUL4-DDB1 E3 ubiquitin ligase complex and is essential for several DNA repair pathways, most notably nucleotide excision repair, where it forms a heterodimer with DDB2 to recognize UV-induced DNA lesions[1][2][4][7][8]. DDB1 serves as an adaptor or scaffold, bridging substrate receptors and the cullin core, thereby facilitating ubiquitination and turnover of numerous protein substrates involved in DNA repair, replication, chromatin remodeling, and cell cycle control[1][2][3][4]. Mutations in the DDB1 complex underlie the rare skin cancer syndrome xeroderma pigmentosum group E, and DDB1 is exploited by certain viruses (e.g., paramyxoviruses, HBV) to degrade host restriction factors[3][4]. While DDB1 has not been therapeutically targeted directly, its central role in maintaining genome stability makes it of high research and translational interest[2][4].

Other names
Damage-specific DNA binding protein 1DDBaXAP1XAP-1UV-DDB 1XPE-BFXPCeDDB p127 subunitDNA damage-binding protein aHBV X-associated protein 1UV-damaged DNA-binding factorUV-damaged DNA-binding protein 1XPE-binding factorXeroderma pigmentosum group E-complementing proteinDDBAUV-DDB1WHIKERSXPCEXPE127kDa
02

Mechanism of action

For drug discovery, potential mechanisms may include modulation of DNA repair or CUL4-DDB1 ubiquitin E3 ligase activity, but no clinical agents are established

03

Biological functions

DNA repair (nucleotide excision repair, especially UV-induced lesion recognition)Protein ubiquitination (via E3 ligase complexes)Cell cycle regulationRegulation of transcriptionChromatin remodelingDNA replication
04

Disease associations

CancerXeroderma pigmentosum group E (XPE)Viral infection (e.g., exploited by certain viruses to override host defenses)
05

Safety considerations

Essential for genome integrity; inhibition is likely to be cytotoxicBroad involvement in cell cycle and DNA repair raises toxicity concerns if targeted therapeutically
06

Interacting drugs

None established; no approved drugs directly target DDB1 as a primary mechanism
07

Biomarkers

DDB1 mutations or expression as a marker for xeroderma pigmentosum group EGenomic integrity/damage response readouts (research use)

Beyond the preview

Go deeper on DNA damage-binding protein 1 (DDB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA damage-binding protein 1 (DDB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call